The Affect On Immune Function Of Non-metastasis Renal Cell Carcinoma Patients With The Treatment Of Autologous Tumour Cell Vaccines

Renal cancer which is also called renal cell carcinoma (RCC) ,renal adenocarcinoma , accounts for 2%-3% of adult malignant cancer cases. In our country,its incidence is only less than bladder cancer,ranking the second place in the malignant cancer of the Urinary system,and the incidence of RCC has a trend to increase year by year.There are more and more asymptomatic renal cell carcinomas being diagnosed,and it has become a serious threat to the health of the people. All of the traditional treatments except surgery for RCC, including the radiotherapy and the chemotherapy have little effect.Thus, the adjuvant treatment for advanced RCC and RCC after radical operation has always been a hot research. Because RCC is one of the most immunoresponsive cancers in humans, immunotherapy has become one of the most important adjuvant therapy .Now, there are a lot of immunotherapies for RCC, including cytokine therapy, adoptive immunotherapy and cancer vaccine therapy. Among these methods, cancer vaccine therapy is the most studied treatment. Now, this paper summarized the medical records of 19 patients the past year who accept autologous tumour cell vaccines with renal cell carcinoma treated at department of Uroiogy of Jilin University China-Japan Union Hospital to investigate the affect on immune function of non-metastasis renal cell carcinoma patients with the treatment of autologous tumour cell Objective:To investigate the affect on immune function of non-metastasis renal cell carcinoma patients with the treatment of autologous tumour cell vaccinesPatients and Methods:We retrospectively reviewed the medical records of 19 patients who accept autologous tumour cell vaccines with renal cell carcinoma treated at department of Uroiogy of Jilin University China-Japan Union Hospital from December 2009 to November 2010. All of them were diagnosed RCC (pT1–3b pN0, M0). After Radical nephrectomy, we keeped some tumor tissue, and made it into autologous tumor vaccine. According to the different requirements of the patients, we give them different treatment (4 times as one treatment, 1 injection weekly) We collected peripheral blood of 19 patients before radical nephrectomy and after vaccination for one treatment, respectively, then used flow cytometer (FCM) to detect the percentage of the Lymphocyte subsets (CD3+ CD4+ CD8+ CD4/CD8 CD56+), compared the change between the two results.The date was processed by statistics software of SPSS17.0.Results: Affter vaccination with autologous tumor vaccine, 19 patients were well tolerated without serious side effects, and their percentage of the Lymphocyte subsets including CD3+ CD4+ CD8+ CD4/CD8 and CD56+ were significantly improved,which reached statistical significance (p<0.05)Conclusion: Autologous tumor vaccine as an adjuvant therapy for the patients with non-metastasis renal cell carcinoma after radical nephrectomy is safe and effective,it can significantly improve the percentage of CD3 +, CD4 +, CD8 +,CD56+ and CD4/CD8, thus,the immune function of the patient could be improved. And the affect on the survival, need a further follow-up to investigate.